我国学者在糖尿病缺血性血管疾病发生机制方面的研究取得重要进展

2017-02-14 朱元贵、郭峻莉、江虎军 医学科学部

在国家自然科学基金项目(项目编号:91639111,81573435)等资助下,温州医科大学中美糖尿病并发症研究所谭毅研究组在糖尿病缺血性血管疾病发生的调控机制研究中取得重要进展。相关研究成果以“Elevating CXCR7 Improves Angiogenic Function of EPCs via Akt/GSK-3β/Fyn-Mediated Nrf2 Activation in Di



在国家自然科学基金项目(项目编号:91639111,81573435)等资助下,温州医科大学中美糖尿病并发症研究所谭毅研究组在糖尿病缺血性血管疾病发生的调控机制研究中取得重要进展。相关研究成果以“Elevating CXCR7 Improves Angiogenic Function of EPCs via Akt/GSK-3β/Fyn-Mediated Nrf2 Activation in Diabetic Limb Ischemia”(CXCR7过Akt/GSK-3β/Fyn信号途径激活Nrf2增强内皮祖细胞在糖尿病下肢缺血中的血管生成功能)为题于2017年1月30日在Circulation Research上在线发表。论文链接:http://circres.ahajournals.org/content/early/2017/01/29/CIRCRESAHA.117.310619。

血管并发症是糖尿病患者致残和致死的主要原因。糖尿病血管并发症主要是由糖尿病氧化损伤所致血管重塑和血管生成功能失调、对缺血/缺氧刺激的反应性降低、血管修复功能受损或异常引起的。内皮祖细胞(endothelial progenitor cells,EPCs)在血管再生过程中起关键作用,但糖尿病能够导致外周EPCs数量减少、血管形成功能受损,其机制至今未明。谭毅教授的研究团队前期研究发现,基质细胞衍生因子(SDF-1)受体CXCR7在EPCs细胞膜上表达,并且参与EPCs的存活、增殖、粘附、跨内皮迁移和血管形成等重要病理生理过程。该团队与合作者进一步研究发现,糖尿病小鼠(db/db)体内的EPCs或体外高糖/高脂处理后的EPCs,CXCR7表达均显着降低,并伴随氧化损伤、凋亡和血管形成功能受损;慢病毒介导CXCR7过表达可显着抑制上述病理变化,并有效促进糖尿病缺血性血管再生和血流恢复。进一步机制研究表明,CXCR7的保护效应主要通过Akt/GSK-3β/Fyn信号途径介导抗氧化转录调节因子Nrf2的核转位和转录激活,从而增强EPCs的抗氧化和血管生成能力。该研究表明,糖尿病诱导的CXCR7下调是糖尿病导致EPCs功能障碍的主要原因,趋化因子受体CXCR7和转录调节因子Nrf2可能是治疗糖尿病缺血性血管疾病的重要靶点。

图 SDF-1/CXCR7在糖尿病EPCs中的作用示意图。糖尿病降低EPCs中CXCR7的表达,并抑制Akt/GSK-3β/Fyn信号介导的Nrf2核转位和下游靶基因的转录激活,从而引起氧化应激的增加,导致EPCs存活下降和血管生成功能受损。

参考文献:Xiaozhen Dai,Xiaoqing Yan,Jun Zeng,et al.Elevating CXCR7 Improves Angiogenic Function of EPCs via Akt/GSK-3β/Fyn-Mediated Nrf2 Activation in Diabetic Limb Ischemia.Circulation Research.January 30.2017

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2070578, encodeId=236020e0578c9, content=<a href='/topic/show?id=a13a54112f5' target=_blank style='color:#2F92EE;'>#我国学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54112, encryptionId=a13a54112f5, topicName=我国学者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 23 14:49:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026372, encodeId=c1a920263e2f3, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Oct 22 12:49:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892831, encodeId=bf9d1892831e0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Sep 29 01:49:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176814, encodeId=d3091e681462, content=创新性强, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:43:25 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498115, encodeId=051114981150b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511305, encodeId=14311511305bf, content=<a href='/topic/show?id=0a493e89802' target=_blank style='color:#2F92EE;'>#发生机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37898, encryptionId=0a493e89802, topicName=发生机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=188310331118, createdName=ms6390871039024434, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2070578, encodeId=236020e0578c9, content=<a href='/topic/show?id=a13a54112f5' target=_blank style='color:#2F92EE;'>#我国学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54112, encryptionId=a13a54112f5, topicName=我国学者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 23 14:49:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026372, encodeId=c1a920263e2f3, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Oct 22 12:49:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892831, encodeId=bf9d1892831e0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Sep 29 01:49:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176814, encodeId=d3091e681462, content=创新性强, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:43:25 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498115, encodeId=051114981150b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511305, encodeId=14311511305bf, content=<a href='/topic/show?id=0a493e89802' target=_blank style='color:#2F92EE;'>#发生机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37898, encryptionId=0a493e89802, topicName=发生机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=188310331118, createdName=ms6390871039024434, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2070578, encodeId=236020e0578c9, content=<a href='/topic/show?id=a13a54112f5' target=_blank style='color:#2F92EE;'>#我国学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54112, encryptionId=a13a54112f5, topicName=我国学者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 23 14:49:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026372, encodeId=c1a920263e2f3, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Oct 22 12:49:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892831, encodeId=bf9d1892831e0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Sep 29 01:49:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176814, encodeId=d3091e681462, content=创新性强, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:43:25 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498115, encodeId=051114981150b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511305, encodeId=14311511305bf, content=<a href='/topic/show?id=0a493e89802' target=_blank style='color:#2F92EE;'>#发生机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37898, encryptionId=0a493e89802, topicName=发生机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=188310331118, createdName=ms6390871039024434, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2070578, encodeId=236020e0578c9, content=<a href='/topic/show?id=a13a54112f5' target=_blank style='color:#2F92EE;'>#我国学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54112, encryptionId=a13a54112f5, topicName=我国学者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 23 14:49:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026372, encodeId=c1a920263e2f3, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Oct 22 12:49:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892831, encodeId=bf9d1892831e0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Sep 29 01:49:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176814, encodeId=d3091e681462, content=创新性强, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:43:25 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498115, encodeId=051114981150b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511305, encodeId=14311511305bf, content=<a href='/topic/show?id=0a493e89802' target=_blank style='color:#2F92EE;'>#发生机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37898, encryptionId=0a493e89802, topicName=发生机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=188310331118, createdName=ms6390871039024434, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-02-18 1ddf0692m34(暂无匿称)

    创新性强

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2070578, encodeId=236020e0578c9, content=<a href='/topic/show?id=a13a54112f5' target=_blank style='color:#2F92EE;'>#我国学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54112, encryptionId=a13a54112f5, topicName=我国学者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 23 14:49:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026372, encodeId=c1a920263e2f3, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Oct 22 12:49:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892831, encodeId=bf9d1892831e0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Sep 29 01:49:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176814, encodeId=d3091e681462, content=创新性强, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:43:25 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498115, encodeId=051114981150b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511305, encodeId=14311511305bf, content=<a href='/topic/show?id=0a493e89802' target=_blank style='color:#2F92EE;'>#发生机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37898, encryptionId=0a493e89802, topicName=发生机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=188310331118, createdName=ms6390871039024434, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2070578, encodeId=236020e0578c9, content=<a href='/topic/show?id=a13a54112f5' target=_blank style='color:#2F92EE;'>#我国学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54112, encryptionId=a13a54112f5, topicName=我国学者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sat Dec 23 14:49:00 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026372, encodeId=c1a920263e2f3, content=<a href='/topic/show?id=4c02960e649' target=_blank style='color:#2F92EE;'>#重要进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96076, encryptionId=4c02960e649, topicName=重要进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Oct 22 12:49:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892831, encodeId=bf9d1892831e0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Sep 29 01:49:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176814, encodeId=d3091e681462, content=创新性强, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:43:25 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498115, encodeId=051114981150b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511305, encodeId=14311511305bf, content=<a href='/topic/show?id=0a493e89802' target=_blank style='color:#2F92EE;'>#发生机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37898, encryptionId=0a493e89802, topicName=发生机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=188310331118, createdName=ms6390871039024434, createdTime=Thu Feb 16 03:49:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]

相关资讯

BJSM:久坐或许并不会诱发糖尿病

日前,一项发表于国际杂志British Journal of Sports Medicine上的研究报告中,来自悉尼大学的研究人员通过研究发现,久坐或许并不会像我们之前认为的那样致命,而且久坐或许并不是引发糖尿病的直接原因。文章中研究人员阐明了多种复杂因素来确定久坐是否会对机体健康产生影响。

诱导肝细胞重编程为胰腺细胞有助于糖尿病患者

【改变单个基因的活性将来自肝脏的细胞重编程为产生胰腺的前体细胞,帮助糖尿病患者】现在可以通过改变单个基因的活性将来自肝脏的细胞重编程为产生胰腺的前体细胞。在亥姆霍兹协会(MDC)的MaxDelbrück分子医学中心的一组研究人员现在已经在小鼠中完成了这项研究。他们的结果应该可以通过细胞治疗帮助糖尿病患者。

Diabetes care:新的糖尿病生物标记物!

糖尿病不同亚型的表征是一个动态的临床研究领域和讨论的活跃领域。近期,一项发表在杂志Diabetes care上的研究旨在确定神经内分泌自身抗原IA-2(ICA512)上新的抗原决定因素,并评估年轻人和成人糖尿病人群中针对新IA-2表位识别自身免疫性糖尿病的循环自身抗体。研究使用检测针对神经内分泌自身抗原IA-2(IA-2ec)的细胞外结构域的自身抗体的新生物标志物评价临床诊断为2型糖尿病(n =

腹胀1年半,加重1个月,不仅是糖尿病

患者老年男性,慢性起病,表现为大量胸腹腔积液,胸腔积液以右侧为主,肝大,双下肢水肿。

2月9日Nature杂志精选文章一览

【1】封面故事: 来自寒武纪的早期后口动物 doi | 10.1038/nature21072 本期封面所示为冠状皱囊动物(Saccorhytus coronarius)的复原图。冠状皱囊动物是一种新发现的后口动物,生活在寒武纪最早期的中国。后口动物包含了脊椎动物、海星、肠鳃纲动物和尾索动物等物种。但由于种类繁多,且缺乏现存的形态中间体,人

儿童肥胖管理新指南更新

儿童肥胖是一个全球性健康问题,严重影响成年期健康及寿命,约影响着美国17%的儿童及青少年。